BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

809 related articles for article (PubMed ID: 35774794)

  • 21. An autophagy-related prognostic signature associated with immune microenvironment features of uveal melanoma.
    Zheng Z; Zhang L; Tu Z; Deng Y; Yin X
    Biosci Rep; 2021 Mar; 41(3):. PubMed ID: 33682883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk stratification of lung adenocarcinoma using a nomogram combined with ferroptosis-related LncRNAs and subgroup analysis with immune and N6-methyladenosine modification.
    Gao C; Kong N; Zhang F; Tang T; Li J; Ding H; Sun Z; Wu L; Xu M
    BMC Med Genomics; 2022 Jan; 15(1):15. PubMed ID: 35093068
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrated clinical characteristics and omics analysis identifies a ferroptosis and iron-metabolism-related lncRNA signature for predicting prognosis and therapeutic responses in ovarian cancer.
    Feng S; Yin H; Zhang K; Shan M; Ji X; Luo S; Shen Y
    J Ovarian Res; 2022 Jan; 15(1):10. PubMed ID: 35057848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Construction and validation of a pyroptosis-related gene signature associated with the tumor microenvironment in uveal melanoma.
    Zhang F; Deng Y; Wang D; Wang S
    Sci Rep; 2022 Jan; 12(1):1640. PubMed ID: 35102195
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenic profiling of metastatic uveal melanoma discerns a potential signature related to prognosis.
    Wang J; Liu M; Sun J; Zhang Z
    J Cancer Res Clin Oncol; 2024 Jan; 150(1):23. PubMed ID: 38246894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development and validation of a ferroptosis-related lncRNAs signature to predict prognosis and microenvironment for melanoma.
    Ping S; Gong R; Lei K; Qing G; Zhang G; Chen J
    Discov Oncol; 2022 Nov; 13(1):125. PubMed ID: 36371574
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of Survival-Related Metabolic Genes and a Novel Gene Signature Predicting the Overall Survival for Patients with Uveal Melanoma.
    Guo X; Yu X; Li F; Xia Q; Ren H; Chen Z; Xing Y
    Ophthalmic Res; 2022; 65(5):516-528. PubMed ID: 35390784
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ferroptosis-Related Long Noncoding RNA Signature Predicts Prognosis of Clear Cell Renal Carcinoma.
    Liu JW; Supandi F; Dhillon SK
    Folia Biol (Praha); 2022; 68(1):1-15. PubMed ID: 36201853
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization and validation of a ferroptosis-related LncRNA signature as a novel prognostic model for lung adenocarcinoma in tumor microenvironment.
    Wang Y; Lu G; Xue X; Xie M; Wang Z; Ma Z; Feng Y; Shao C; Duan H; Pan M; Ding P; Li X; Han J; Yan X
    Front Immunol; 2022; 13():903758. PubMed ID: 36016939
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A prognostic signature based on the expression profile of the ferroptosis-related long non-coding RNAs in hepatocellular carcinoma.
    Lin X; Yang S
    Adv Clin Exp Med; 2022 Oct; 31(10):1099-1109. PubMed ID: 35581934
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Novel Ferroptosis-Related Long Non-Coding RNA Prognostic Signature Correlates With Genomic Heterogeneity, Immunosuppressive Phenotype, and Drug Sensitivity in Hepatocellular Carcinoma.
    Li G; Liu Y; Zhang Y; Xu Y; Zhang J; Wei X; Zhang Z; Zhang C; Feng J; Li Q; Wang G
    Front Immunol; 2022; 13():929089. PubMed ID: 35874689
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A prognostic model based on immune-related long noncoding RNAs for patients with epithelial ovarian cancer.
    Peng Y; Wang H; Huang Q; Wu J; Zhang M
    J Ovarian Res; 2022 Jan; 15(1):8. PubMed ID: 35031063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a novel hypoxia-immune-related LncRNA risk signature for predicting the prognosis and immunotherapy response of colorectal cancer.
    Luan L; Dai Y; Shen T; Yang C; Chen Z; Liu S; Jia J; Li Z; Fang S; Qiu H; Cheng X; Yang Z
    Front Immunol; 2022; 13():951455. PubMed ID: 36189298
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ferroptosis-related long non-coding RNA signature predicts the prognosis of bladder cancer.
    Hou J; Lu Z; Cheng X; Dong R; Jiang Y; Wu G; Qu G; Xu Y
    BMC Cancer; 2022 Jun; 22(1):719. PubMed ID: 35768833
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrated analysis of a competing endogenous RNA network reveals a ferroptosis-related 6-lncRNA prognostic signature in clear cell renal cell carcinoma.
    Zheng Q; Gong Z; Lin S; Ou D; Lin W; Shen P
    Adv Clin Exp Med; 2024 Mar; ():. PubMed ID: 38470002
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of Ferroptosis-Associated Long Noncoding RNA Prognostic Model and Tumor Immune Microenvironment in Thyroid Cancer.
    Lin Y; Gan F; He X; Deng H; Li Y
    J Immunol Res; 2022; 2022():5893998. PubMed ID: 35915656
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune-related lncRNAs as predictors of survival in breast cancer: a prognostic signature.
    Ma W; Zhao F; Yu X; Guan S; Suo H; Tao Z; Qiu Y; Wu Y; Cao Y; Jin F
    J Transl Med; 2020 Nov; 18(1):442. PubMed ID: 33225954
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel signature to guide osteosarcoma prognosis and immune microenvironment: Cuproptosis-related lncRNA.
    Yang M; Zheng H; Xu K; Yuan Q; Aihaiti Y; Cai Y; Xu P
    Front Immunol; 2022; 13():919231. PubMed ID: 35967366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification and validation of tumor microenvironment-related lncRNA prognostic signature for uveal melanoma.
    Liao CL; Hu N; Sun XY; Zhou Q; Tian M; Cao Y; Lyu HB
    Int J Ophthalmol; 2021; 14(8):1151-1159. PubMed ID: 34414077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification and validation of ferroptosis-related lncRNA signature as a prognostic model for skin cutaneous melanoma.
    Guo S; Chen J; Yi X; Lu Z; Guo W
    Front Immunol; 2022; 13():985051. PubMed ID: 36248853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.